

## Comment Re: MDA-MB-435 and M14 Cell Lines: Identical but not M14 Melanoma?

### To the Editor:

In support of the recent article by Chambers (1), we wish to share our data on the origin of the MDA-MB-435 and M14 cell lines. Chambers claims that it is most plausible that both cell lines represent MDA-MB-435 based on two X chromosomes in the MDA-MB-435 karyotype, whereas M14 had been derived from a man (1). However, karyotyping does not discriminate between paternal and maternal alleles and thus does not exclude loss of the Y chromosome combined with reduplication of the X chromosome. We previously reported an allelotyping on human breast cancer cell lines, including MDA-MB-435 (2). Our analyses did not detect Y chromosome sequences and revealed heterozygosity of polymorphic microsatellite markers at Xp, implying that MDA-MB-435 had indeed been derived from a woman. Our MDA-MB-435 cell line was obtained directly from American Type Culture Collection at passage 239 and M14 from its originator at passage 10 (3). We confirmed that the cell lines were identical by microsatellite analysis, in concordance with Rae and colleagues (4), and we also identified unique mutations in the *p53* and *p16* genes in both cell lines (3). Altogether, it can be concluded conclusively that MDA-MB-435 and M14 are breast cancer cell lines.

The melanocytic phenotype of MDA-MB-435 may be explained by our recent molecular characterization of MDA-MB-435 and 40 other human breast cancer cell lines (3). Microarray gene expression profiling had revealed two major subgroups among the breast cancer cell lines: luminal type and basal type. As anticipated, MDA-MB-435 was basal type, along with 14 other cell lines, and unsupervised hierarchical clustering showed strong similarity among the basal-type cell lines. It is unlikely that the 15 basal-type cell lines all are of melanocytic origin because 4 of them carry a *BRCAl* mutation and 1

has the *CHEK2* 1100delC mutation. Also, 10 of the basal-type cell lines, including MDA-MB-435, are of the normal-like intrinsic subtype; a molecular subtype that had been defined on (uncultured) clinical breast tumors. Most interestingly, analysis of the genetic status of 27 well-known cancer genes in our collection of breast cancer cell lines identified two subtype-specific gene mutation profiles (3). The basal mutation profile involved mutations in the *BRCAl*, *RBI*, *RAS*, and *BRAF* genes and deletions of *p16* and *p14ARF*. Particularly, the combination of mutations in *p16*, *RBI*, and *RAS* pathway genes is characteristic for melanoma. These results thus suggest that basal-type breast cancers may have a genetic basis similar to melanomas, explaining their melanocytic phenotype and perhaps also their rather aggressive clinical course.

**Antoinette Hollestelle**

**Mieke Schutte**

Department of Medical Oncology,  
Josephine Nefkens Institute,  
Erasmus University Medical Center,  
Rotterdam, the Netherlands

### Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

### References

1. Chambers AF. MDA-MB-435 and M14 cell lines: identical but not M14 melanoma? *Cancer Res* 2009;69:5292-3.
2. Harkes IC, Elstrodt F, Dinjens WN, et al. Allelotyping of 28 human breast cancer cell lines and xenografts. *Br J Cancer* 2003;89:2289-92.
3. Hollestelle A, Nagel JHA, Smid M, et al. Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines. *Breast Cancer Res Treat* 2009;DOI: 10.1007/s10549-009-0460-8.
4. Rae JM, Creighton CJ, Meck JM, Haddad BR, Johnson MD. MDA-MB-435 cells are derived from M14 melanoma cells—a loss for breast cancer, but a boon for melanoma research. *Breast Cancer Res Treat* 2007;104:13-9.

Published OnlineFirst 9/1/09.

©2009 American Association for Cancer Research.  
doi:10.1158/0008-5472.CAN-09-2396

# Cancer Research

The Journal of Cancer Research (1916–1930) | The American Journal of Cancer (1931–1940)

## Comment Re: MDA-MB-435 and M14 Cell Lines: Identical but not M14 Melanoma?

Antoinette Hollestelle and Mieke Schutte

*Cancer Res* 2009;69:7893. Published OnlineFirst September 1, 2009.

**Updated version** Access the most recent version of this article at:  
doi:[10.1158/0008-5472.CAN-09-2396](https://doi.org/10.1158/0008-5472.CAN-09-2396)

**Cited articles** This article cites 3 articles, 1 of which you can access for free at:  
<http://cancerres.aacrjournals.org/content/69/19/7893.full#ref-list-1>

**Citing articles** This article has been cited by 4 HighWire-hosted articles. Access the articles at:  
<http://cancerres.aacrjournals.org/content/69/19/7893.full#related-urls>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link  
<http://cancerres.aacrjournals.org/content/69/19/7893>.  
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.